GL1X · GenesisL1 explorer

Research workbench

14-3-3 sigma with RELA/P65 binding site PS45 and covalently bound TCF521-083

Analyse 14-3-3 sigma with RELA/P65 binding site PS45 and covalently bound TCF521-083 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7O6J
Type
protein
Length
235 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
14-3-3 protein sigma; Transcription factor P65
UniProt
P31947, Q04206
Ligands
V48, CL
Pockets
1 · best druggability 0.53

Structure

x-ray diffraction · 2 distinct chains · 80% helix, 0% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A14-3-3 protein sigmaprotein22683% helix, 0% strandP31947
PTranscription factor P65protein90% helix, 0% strandQ04206

Ligands and binding sites

  • V48 · (5-methanoyl-2-nitro-phenyl) 2-(3-methoxyphenyl) ethanoate · ligand · 3 copies · chains A, P
  • CL · Chloride ion · ion · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11780.530.7826V48

Interfaces

1 interface between chains.

  • A–P · 620 Ų buried · 15 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 3 covalent, 2 modified (covalent ligand, oxidation, phosphorylation).

Compared structures

  • 7O6J · 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-083 · the same entry in another collection · chain A against A, TM-score 1.00
  • P31947 · AlphaFold monomer V2.0 prediction for 14-3-3 protein sigma (P31947) · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.